Biotage and CEO Torben Jörgensen have agreed to extend period of service
Biotage’s Board of Directors and Torben Jörgensen have agreed to extend Torben Jörgensen’s current employment contract as Biotage’s CEO and President up and until April 2020 when Torben Jörgensen will be 68 years old. According to the previous contract, Torben Jörgensen would leave Biotage April 2019.
This information was submitted for publication, through the agency of the contact persons set out above, at 14.00 on May 9, 2018.
Biotage offers efficient separation technologies from analysis to industrial-scale and high-quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage’s products are used by public authorities, academic institutions, contract research and contract manufacturing organizations and in the pharmaceutical and food industries, among others. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan, South Korea and India. Biotage has approx. 400 employees and had sales of 748 MSEK in 2017. Biotage is listed on Nasdaq Stockholm. Website: www.biotage.com